Evolution of plasma specific fibrin degradation products during thrombolytic therapy in patients with thrombo-embolism.
Faivre
R
R
Service de cardiologie, hôpital St Jacques, Besancon, France.
Mirshahi
M
M
Ducellier
D
D
Soria
C
C
Soria
J
J
Mirshahi
M
M
Kieffer
Y
Y
Bassand
J P
JP
Caen
J
J
Maurat
J P
JP
D000328:Adult; D000368:Aged; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011859:Radiography; D013300:Streptokinase / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator